Search results
Showing 856 to 870 of 1308 results for social care
Baricitinib for treating moderate to severe atopic dermatitis (TA681)
Evidence-based recommendations on baricitinib for treating moderate to severe atopic dermatitis in adults.
from children's to adults' services for young people using health or social care services Number NG43 Date issued February 2016
Evidence-based recommendations on leniolisib (Joenja) for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over.
Physical activity: for NHS staff, patients and carers (QS84)
This quality standard covers encouraging physical activity in people of all ages who are in contact with the NHS, including staff, patients and carers. It describes high-quality care in priority areas for improvement.
View quality statements for QS84Show all sections
Sections for QS84
- Quality statements
- Quality statement 1: Advice for adults during NHS Health Checks
- Quality statement 2: Advice for parents or carers as part of the Healthy Child Programme 2-year review
- Quality statement 3: Advice for parents or carers as part of the National Child Measurement Programme
- Quality statement 4: Implementing a physical activity programme for employees in NHS organisations
- Update information
- About this quality standard
are relevant to patients and health and social care services (for example, quality of life, hospital and care home...
Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)
Evidence-based recommendations on tildrakizumab (Ilumetri) for treating moderate to severe plaque psoriasis in adults.
Evidence-based recommendations on Episcissors-60 for mediolateral episiotomy.
Early value assessment (EVA) guidance on virtual reality technologies for treating agoraphobia or agoraphobic avoidance.
What training, support or interventions help to reduce caring-related accidents or incidents?
understanding of the health condition, disability or needs of the person they care for, so the committee recommended carer-specific...
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)
Evidence-based recommendations on certolizumab pegol (Cimzia) for treating moderate to severe plaque psoriasis in adults.
Evidence-based recommendations on pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults.
Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (TA151)
Evidence-based recommendations on continuous subcutaneous insulin infusion (insulin pump therapy) for treating type 1 diabetes in adults and children.
NICE has a developed medtech innovation briefing on Mollii suit for spasticity .
Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)
Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection